GlassScriptPhysician profile
Jeffrey D Harris
NPI 1922070812
$4,458.37
in general payments reported to CMS, 2019-2025
32 companies · $931 in 2025
The $931 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12.42 · 2020: $64.04 · 2021: $678 · 2022: $1,210 · 2023: $1,152 · 2024: $412 · 2025: $931.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,382 · Education: $112.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,382.15 |
| Education | $112.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $702.21 | 2019-2025 | Trelegy Ellipta, Arexvy, Nucala |
| Jazz Pharmaceuticals INC. | $607.93 | 2021-2024 | Xywav |
| Harmony Biosciences LLC | $577.41 | 2022-2025 | Wakix |
| Astrazeneca Pharmaceuticals LP | $498.36 | 2020-2025 | Fasenra, Breztri, Airsupra |
| Insmed, INC. | $314.17 | 2022-2025 | Arikayce, Brinsupri |
| Regeneron Healthcare Solutions, INC. | $230.68 | 2023-2025 | Dupixent |
| Genzyme Corporation | $197.90 | 2022-2025 | |
| Axsome Therapeutics, INC. | $185.29 | 2023-2024 | Sunosi |
| Teva Pharmaceuticals USA, INC. | $146.00 | 2022-2023 | |
| Philips North America LLC | $125.16 | 2021-2025 | (8874) Incourage, Vest Therapy Und |
| Resmed Corp | $101.85 | 2022-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $90.28 | 2021-2025 | Ofev |
| Takeda Pharmaceuticals U.S.A., INC. | $88.32 | 2021-2024 | Glassia |
| Alcon Vision LLC | $69.07 | 2023 | Rocklatan |
| Electromed, INC. | $60.35 | 2021-2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avadel Cns Pharmaceuticals, LLC | $44.58 | 2024-2025 | Lumryz |
| Verona Pharma, INC. | $43.93 | 2025 | Ohtuvayre |
| Eisai INC. | $41.68 | 2020-2021 | |
| Pfizer INC. | $40.22 | 2022-2024 | |
| Grifols USA, LLC | $40.06 | 2022-2025 | Prolastin-C Liquid |
| Arbor Pharmaceuticals, INC. | $37.55 | 2021 | |
| Idorsia Pharmaceuticals US INC | $31.82 | 2022-2023 | Quviviq |
| Merck Sharp & Dohme LLC | $27.48 | 2023 | Belsomra |
| Mylan Specialty L.P. | $27.25 | 2021-2023 | Yupelri |
| Abbvie INC. | $24.05 | 2021-2022 | |
| Amgen INC. | $23.41 | 2023 | Tavneos |
| E.R. Squibb & Sons, L.L.C. | $20.04 | 2022 | |
| Baxter Healthcare | $18.38 | 2023 | Hillrom - Life 2000 Ventilation System |
| Actelion Pharmaceuticals US, INC. | $16.51 | 2022 | |
| Currax Pharmaceuticals LLC | $13.58 | 2022 | |
| Fisher & Paykel Healthcare INC | $12.85 | 2023 | Fisher & Paykel Healthcare |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Harris listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.